DaVita Inc.

$178.72$0.03 (+0.02%)
Last updated on --.

DaVita Inc. price

24 Hours+0.02%+$0.03
30 days-2.98%-$5.490
60 days-3.12%-$5.728
90 days-22.83%-$52.68

About DaVita Inc.

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

Stock ticker
DVA
Company
DaVita Inc.
Industry
Healthcare
Category
US
Stock split / reverse split
12
Launch date
Oct 31, 1995
Listed exchange
NYSE

Financials

Q2 FY2026 Earnings
Report period: Apr 1, 2026 – Jun 30, 2026

Summary: DVA reported Revenue of 3.55B (+5.17%), beating expectations; EPS of 4.02 (+36.27%), beating expectations.

Revenue (USD)Beat3.55B+5.16%3.50B+1.55%57.74M+1.65%
EPS (USD)Beat4.02+36.27%3.88+43.70%0.14+3.60%
Financial estimates
● Actual● Estimate
Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
2.582.042.452.874.02
+3.20%-18.40%-20.72%+43.50%+55.81%
● EPS● YoY
Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
17.49B17.74B17.48B17.50B17.71B
15.94B16.22B16.32B16.45B16.63B
91.12%91.38%93.37%94.01%93.90%
● Assets● Liabilities● Ratio
Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
324.39M841.37M540.73M320.83M490.07M
-59.40%+3.82%-1.27%+78.23%+51.07%
● CFO● YoY

Shareholders

Shareholders
BERKSHIRE HATHAWAY INC44.69%
BLACKROCK, INC.3.79%
VANGUARD CAPITAL MANAGEMENT LLC3.24%
MORGAN STANLEY2.47%
VANGUARD PORTFOLIO MANAGEMENT LLC2.12%
Others43.65%
Institutions
% Owned91.65%-0.48%
Shares held59.38M-2.71M
Institutions665+54
% OwnedPrice
Name% OwnedChange
BERKSHIRE HATHAWAY INC44.69%--
BLACKROCK, INC.3.79%-305.76K
VANGUARD CAPITAL MANAGEMENT LLC3.24%-78.80K
MORGAN STANLEY2.47%-64.33K
VANGUARD PORTFOLIO MANAGEMENT LLC2.12%-101.69K

Dividends

Stock splits
Launch date: Oct 31, 1995
DateRatio
Sep 9, 20131 → 2
Jun 16, 20042 → 3
Oct 21, 19973 → 5

DaVita Inc. conversion tables

DVADVA
USDUSD
0.5 DVA89.36 USD
1 DVA178.72 USD
5 DVA893.6 USD
10 DVA1,787.2 USD
USDUSD
DVADVA
0.5 USD0.0027977 DVA
1 USD0.0055953 DVA
5 USD0.027977 DVA
10 USD0.055953 DVA

More to explore

FAQ

DVA is trading at $178.72, +0.02% over the last 24 hours. Track live moves on the price chart at the top of this page.

The DVA stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. DVA is currently trading at $178.72, +0.02% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on DVA price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Healthcare sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.

P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. DVA's P/E ratio is currently 15.68 — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from DVA; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against DVA's historical range and other companies in the Healthcare sector.

DaVita Inc.'s market cap is currently 11.45B USD. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.